Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform Business Wire Kite sails into in vivo CAR-T space via $350M Interius buyout Fierce Biotech Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million statnews.com Gilead Sciences to Buy Interius BioTherapeutics for $350 Million MarketScreener Gilead’s Kite buying Interius BioTherapeutics for $350M Seeking Alpha Source link
Read More »